Background
• The Food and Drug Administration (FDA) defines a patient-reported outcome (PRO) as "any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else". • In 2009, the FDA published guidance for manufacturers entitled "Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims", which explains how the FDA evaluates PRO instruments used in clinical trials when a manufacturer is seeking a PRO label claim. The guidance outlines the considerations for the evaluation and selection of a PRO instrument, clinical trial design, and data analysis. Table 1 provides additional information on the criteria. • In a review of the labels of new molecular entities (NMEs) approved between 1 January 2006 and 31 December 2010, Gnanasakthy and colleagues found that none of the 18 approved oncology NMEs had a PRO claim in the label, compared with 28 of 98 non-oncology NMEs. More than 30 different PRO instruments were used to support label claims relating to symptoms, function, health-related quality of life (HRQL), patient satisfaction, and patient global assessments.
• In 2012, the Center for Medical Technology Policy (CMTP) published an effectiveness guidance document (EGR) that included recommendations for incorporation of PROs into oncology studies (Basch et al. 2012) . The document responds to the emphasis that major funding, policy-making, and regulatory agencies in the US have placed on the incorporation of PROs into oncology research, including the National Cancer Institute, American Cancer Society, Centers for Medicare and Medicaid Services, FDA, and the National Institutes for Health.
• The EGR provides 15 recommendations relating to the incorporation of PROs into clinical effectiveness research (CER) in adult oncology, including selection of instruments, implementation methods, and data analysis and reporting, summarized in Table 2 . • The CMTP EGR recommends a number of instruments because of their strong psychometric properties and validation in previous clinical cancer research.
• In oncology trials, PROs can provide insight into the patient's perspective on the impact of treatment, burden of disease on patients, and significant prognostic information beyond standard clinical care measures. Improvement in long-term survival rates in some cancers (e.g., breast and testicular cancer) has increased the need for long-term treatments, prompting concern about the impact on symptoms and HRQL.
Objectives
To identify PRO claims on FDA labels that have been approved in oncology and hematology indications since the publication of the FDA guidance, to consider the challenges for sponsors seeking such claims, and to offer solutions to these challenges.
Methods
• Labels were reviewed according to a set process. All hematology and oncology products that were newly approved, had a new or modified indication, or had a label update between 1 January 2010 and 31 December 2014 were identified from the FDA's Hematology/Oncology (Cancer) Approvals & Safety Notifications website, which was accessed on 3 January 2015 (www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm).
• The most recently approved/current label was retrieved for each product identified for review. Where there was a duplication because of updated information becoming available, only the most recent information was reviewed. Notices and other information listed were not reviewed. • For each product identified, the entire label was reviewed for information relating to data captured by a PRO instrument.
Data were extracted by two authors (JT and SS) with final approval and review by a third author (AN). • Where PRO data had been included in the label, the following information was extracted: brand and generic names of product; year of initial FDA approval; new drug application (NDA) or biologic license application (BLA); indication; PRO claim, including approved language; PRO instrument.
Results
• A total of 64 labels met the inclusion criteria for review, of these: • 14 were BLAs; two of these also had new indications approved during the review period following initial approval • 29 were NDAs in the review period; three of these also had new indications approved during the review period following initial approval • 11 were initially approved before 2010 but were approved for a new indication during the review period • 10 were originally approved before 2010 but had updated labels approved in the review period.
• Two of the 64 drugs had PRO efficacy claims: Jakafi and Zytiga, both approved in 2011. The information was found in section 14 of the label (Clinical Studies), where the details and results of clinical trials for the drugs are reported.
• Jakafi is approved for the treatment of high-risk myelofibrosis. The product label states that it improves disease symptoms recorded on the Myelofibrosis Symptom Assessment Form (MFSAF). This instrument is a daily diary that captures the core symptoms of myelofibrosis and provides a daily total symptom score. In trials, patients taking Jakafi had a greater reduction in total symptom score than placebo recipients. • Zytiga is approved for metastatic castration-resistant prostate cancer. The product label states that it improves pain, measured by the short-form Brief Pain Inventory (BPI-SF). In trials, the median time to opiate use for prostate cancer pain was not reached for patients receiving Zytiga, compared with 23.7 months in placebo recipients.
• The label for Xalkori (non-small cell lung cancer [NSCLC] ; approved 2011) includes PRO data to support adverse event reporting (see Table 3 ). The Phase 3 trial included the Visual Symptom Assessment Questionnaire (VSAQ-ALK), which demonstrated that patients receiving Xalkori reported a higher incidence of visual disturbances than those receiving chemotherapy. The information was in section 6 of the approved label (Adverse Reactions).
• Our review also identified language within the indication section of the approved product labels that indicated where there was a lack of data relating to the impact of treatment on disease-related symptoms. Notably, the label for Adcetris stated that no improvement in patient-reported symptoms in either indication (Hodgkin's lymphoma and anaplastic large cell lymphoma) had been established. A further 11 labels stated that there were no data to demonstrate improvement in disease-related symptoms (see Table 4 ). The modified MFSAF is a daily diary capturing the core symptoms of myelofibrosis (abdominal discomfort, pain under left ribs, night sweats, itching, bone/muscle pain, and early satiety). Symptom scores ranged from 0 to 10 with 0 representing symptoms "absent" and 10 representing "worst imaginable" symptoms. These scores were added to create the daily total score, which has a maximum of 60. At baseline, the mean Total Symptom Score was 18.0 in the Jakafi group and 16.5 in the placebo group. A higher proportion of patients in the Jakafi group had a 50% or greater reduction in Total Symptom Score than in the placebo group, with a median time to response of less than 4 weeks. Based on the VSAQ-ALK, patients treated with Xalkori in Study 1 reported a higher incidence of visual disturbances than patients treated with chemotherapy.
The majority of patients in the Xalkori arm of Study 1 (>50%) reported visual disturbances; these visual disturbances occurred at a frequency of 4-7 days each week, lasted up to 1 minute, and had mild or no impact (scores 0 to 3 out of a maximum score of 10) on daily activities as captured in a patient questionnaire. Use in combination with dabrafenib is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated.
Zydelig (idelalisib)
Relapsed chronic lymphocytic leukemia; relapsed follicular B-cell non-Hodgkin's lymphoma (FL); relapsed small lymphocytic lymphoma (SLL) Accelerated approval was granted for FL and SLL based on overall response rate. Improvement in patient survival or disease-related symptoms has not been established. Continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials.
Zykadia (ceritinib)
Anaplastic lymphoma kinasepositive metastatic NSCLC Accelerated approval was based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Discussion
• PRO data have begun to appear in FDA-approved product labels: in contrast to an earlier review of products approved in 2006 -2010 , which found no PRO data on FDA-approved labels, this review (2010 -2014 identified use of PRO data to support efficacy claims and adverse event reporting.
• The FDA clearly wants PRO data that provide information on the impact of treatment on disease-related symptoms to be included on approved product labels; one label included the statement that no improvement in patient-reported symptoms had been established, and a further 12 labels stated that there were no data to demonstrate improvement in disease-related symptoms. The FDA clearly expects to document such data in its labels as evidence of treatment efficacy.
• None of the PRO instruments recommended by the CMTP EGR were used to support these label claims; instead, the BPI-SF, MFSAF, and VSAQ-ALK were used. This partly reflects the FDA's preference for symptom reporting on approved product labels, rather than broader claims relating to HRQL that would be supported by some of the instruments recommended by the CMTP EGR.
• This highlights one of the major challenges facing those working in oncology drug development -the lack of PRO instruments that meet the stringent requirements set out in the FDA's guidance document (FDA, 2009) . Although oncology-specific PRO instruments with strong psychometric properties and validation in clinical cancer research exist, the data from these instruments have not appeared on FDA-approved labels.
• The lack of PRO data on FDA-approved labels does not reflect that extent to which PRO data are being captured in oncology trials. A recent review of evidence from clinicaltrials.gov (2007) (2008) (2009) (2010) (2011) (2012) (2013) found that 29% of trials included a PRO instrument, marginally higher than in non-oncology trials, increasing to 33% when focusing on 2010-2013 (Vodicka et al., 2015) . This indicates a growing emphasis on patient-centered research in oncology and the integration of the patient's perspective into clinical research.
• An article published since this label review was undertaken presents the perspectives of industry, the FDA, and the patient on PROs in cancer drug development and US regulatory review (Basch et al., 2015) and recommends actions to increase PROs on FDA-approved product labels (summarized in Table 5 ).
• The figure below presents a strategic four-step process for PRO endpoint development to help guide those working in oncology towards gaining FDA approval for PRO data on the product label. Table 5 Summary of CMTP recommendations for incorporation of PROs into CER (Basch et al., 2012) • FDA reviewers to proactively encourage inclusion of PROs in drug development programs
• Trial sponsors to develop thoughtful and comprehensive proposals for PRO collection, facilitated by early discussion with the FDA, and justify deviations from PRO guidance
• PRO stakeholders to develop a research agenda to characterize and mitigate the adequacy of existing instruments, the effect of open-label trial design, causes and handling of missing data, and best practice for statistical analysis
• Existing questionnaires to be systematically analyzed; the FDA to endorse those suitable to support label claims
• Stakeholders from industry, patient groups, and the FDA to identify/develop PRO measures that are important to patients and endorsed as such for labelling
• FDA to train staff to accelerate dialog around the development, qualification, implementation, and analysis of PRO measures with multiple stakeholders; PRO experts to be included in reviews to balance methodological issues against what can be realistically achieved
• Industry and academia to develop PRO training programs, possibly including patient advocates
Conclusion

